Cor­rect­ed: Over a year af­ter FDA re­jec­tion, Bio­haven claims suc­cess in piv­otal neu­rode­gen­er­a­tive dis­ease study

Bio­haven is seek­ing to re­verse the fate of its em­bat­tled ex­per­i­men­tal drug tro­r­ilu­zole in spin­ocere­bel­lar atax­ia — a neu­rode­gen­er­a­tive dis­ease — us­ing new clin­i­cal tri­al re­sults that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER